Editorial process EditorialTable4.Comparisonofobservedvaluesversusexpected(reference)valuesfromregistriesinthesameregion. Country, Registry (period) Cancer in Africa Volume III (editorial table 4) International comparison MALE SITE Lip, oral cavity and pharynx Oesophagus Stomach Colon, rectum and anus Liver Pancreas Larynx Lung (incl. trachea) Melanoma of skin Non−melanoma skin Kaposi sarcoma Penis Prostate Testis Kidney etc. Bladder Brain, central nervous system Thyroid Lymphoma Leukaemia Ill−defined (2.9% of total) All sites All sites but non−melanoma skin Cases 117 166 46 92 106 20 20 30 5 26 463 36 351 10 30 22 48 18 177 76 61 2107 2081 SITE Lip, oral cavity and pharynx Oesophagus Stomach Colon, rectum and anus Liver Pancreas Larynx Lung (incl. trachea) Melanoma of skin Non−melanoma skin Kaposi sarcoma Breast Cervix uteri O&U part of uterus Ovary Kidney etc. Bladder Brain, central nervous system Thyroid Lymphoma Leukaemia Ill−defined (2.6% of total) All sites All sites but non−melanoma skin Cases 61 119 30 104 93 19 5 24 14 34 348 431 739 72 96 26 22 30 34 165 56 74 2811 2777 ASR (se) 8.9 ( 1.02) > 19.5 ( 1.66) > 4.9 ( 0.81) 9.3 ( 1.13) 7.5 ( 0.93) 1.7 ( 0.43) 2.7 ( 0.63) 3.0 ( 0.64) 0.7 ( 0.35) 1.4 ( 0.34) < 18.6 ( 1.15) > 3.0 ( 0.60) > 46.8 ( 2.66) > 0.4 ( 0.19) 1.2 ( 0.29) 2.3 ( 0.53) 3.2 ( 0.61) > 1.4 ( 0.44) 8.7 ( 0.93) 3.0 ( 0.49) 3.9 ( 0.63) 162.1 ( 4.49) > 160.8 ( 4.47) > FEMALE ASR (se) 4.1 ( 0.64) 12.1 ( 1.21) > 2.9 ( 0.58) 9.8 ( 1.09) 6.7 ( 0.83) > 2.0 ( 0.50) 0.5 ( 0.24) 2.4 ( 0.53) 1.1 ( 0.35) 1.6 ( 0.35) < 11.2 ( 0.81) > 31.5 ( 1.80) 52.0 ( 2.27) > 6.7 ( 0.89) > 6.8 ( 0.82) > 1.0 ( 0.25) 1.9 ( 0.48) 1.3 ( 0.32) 2.2 ( 0.45) 8.2 ( 0.86) > 2.5 ( 0.45) < 4.8 ( 0.69) 182.0 ( 4.26) > 180.4 ( 4.24) > O/E 1.56 2.01 1.05 1.19 1.21 1.18 1.46 0.86 0.79 0.54 1.99 2.45 1.96 1.47 1.08 0.72 2.53 1.23 1.11 0.79 1.44 1.46 O/E 1.03 1.71 0.72 1.27 1.88 1.38 0.89 1.06 1.00 0.50 2.39 1.05 1.30 2.08 1.34 0.82 0.79 1.25 0.88 1.39 0.70 1.21 1.22 MV(%) 76.1 42.8 43.5 51.1 32.1 40.0 75.0 43.3 100.0 65.4 74.5 61.1 < 43.9 60.0 60.0 45.5 29.2 < 50.0 < 72.9 69.7 32.8 57.9 57.9 DCO(%) 2.6 1.2 4.3 1.1 2.8 5.0 0.0 13.3 0.0 0.0 3.0 0.0 0.9 0.0 0.0 0.0 2.1 0.0 4.0 2.6 0.0 2.1 2.2 ICD-10 C00−14 C15 C16 C18−21 C22 C25 C32 C33−34 C43 C44 C46 C60 C61 C62 C64−66 C67 C70−72 C73 C81−88,C90 C91−95 C76−80 C00−96 C00−96/C44 MV(%) 55.7 < 45.4 23.3 < 51.0 < 31.2 10.5 20.0 < 33.3 50.0 < 70.6 76.1 56.6 < 55.8 59.7 49.0 46.2 63.6 30.0 58.8 < 73.9 75.0 33.8 57.6 57.4 DCO(%) 0.0 0.0 0.0 1.9 2.2 15.8 0.0 4.2 0.0 2.9 1.7 2.1 0.7 2.8 2.1 3.8 0.0 0.0 0.0 3.6 5.4 0.0 1.7 1.7 ICD-10 C00−14 C15 C16 C18−21 C22 C25 C32 C33−34 C43 C44 C46 C50 C53 C54−55 C56 C64−66 C67 C70−72 C73 C81−88,C90 C91−95 C76−80 C00−96 C00−96/C44 Significant lower (<) or higher (>) differences are marked in bold. ASR: rates compared with those estimated in Eastern Africa (source GLOBOCAN 2018) MV(%). Percentages compared with that from 28 cancer registries in Sub−Saharan Africa: Congo, Brazzaville; Benin, Cotonou; Cote d Ivoire, Abidjan; Ethiopia, Addis Ababa; The Gambia; France, Reunion Ghana, Kumasi; Guinea, Conakry; Kenya, Eldoret and Nairobi; Malawi, Blantyre; Mali, Bamako; Mauritius Mozambique, Beira; Namibia; Niger, Niamey; Nigeria, Ibadan, Abuja and Calabar; Seychelles South Africa, national and Eastern Cape; Uganda, Kampala and Gulu; Zambia, Lusaka; Zimbabwe, Bulawayo and Harare (Black) 12